Somatic Mosaicism Caused by Monoallelic Reversion of a Mutation in T Cells of a Patient with ADA‐SCID and the Effects of Enzyme Replacement Therapy on the Revertant Phenotype
Open Access
- 14 June 2011
- journal article
- case report
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 74 (5) , 471-481
Abstract
Patients with adenosine deaminase (ADA) deficiency exhibit spontaneous and partial clinical remission associated with somatic reversion of inherited mutations. We report a child with severe combined immunodeficiency (T‐B‐ SCID) due to ADA deficiency diagnosed at the age of 1 month, whose lymphocyte counts including CD4+ and CD8+ T and NK cells began to improve after several months with normalization of ADA activity in Peripheral blood lymphocytes (PBL), as a result of somatic mosaicism caused by monoallelic reversion of the causative mutation in the ADA gene. He was not eligible for haematopoietic stem cell transplantation (HSCT) or gene therapy (GT); therefore he was placed on enzyme replacement therapy (ERT) with bovine PEG‐ADA. The follow‐up of metabolic and immunologic responses to ERT included gradual improvement in ADA activity in erythrocytes and transient expansion of most lymphocyte subsets, followed by gradual stabilization of CD4+ and CD8+ T (with naïve phenotype) and NK cells, and sustained expansion of TCRγδ+ T cells. This was accompanied by the disappearance of the revertant T cells as shown by DNA sequencing from PBL. Although the patient’s clinical condition improved marginally, he later developed a germinal cell tumour and eventually died at the age of 67 months from sepsis. This case adds to our current knowledge of spontaneous reversion of mutations in ADA deficiency and shows that the effects of the ERT may vary among these patients, suggesting that it could depend on the cell and type in which the somatic mosaicism is established upon reversion.Keywords
This publication has 28 references indexed in Scilit:
- More than just SCID—The phenotypic range of combined immunodeficiencies associated with mutations in the recombinase activating genes (RAG) 1 and 2Clinical Immunology, 2010
- How I treat ADA deficiencyBlood, 2009
- Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patientClinical Immunology, 2009
- Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiencyBlood, 2008
- Cerebral Lymphoma in an Adenosine Deaminase–Deficient Patient With Severe Combined Immunodeficiency Receiving Polyethylene Glycol–Conjugated Adenosine DeaminasePediatrics, 2005
- Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patientsEuropean Journal of Immunology, 2005
- Liver disease in children with primary immunodeficienciesThe Journal of Pediatrics, 2004
- In vivo reversion to normal of inherited mutations in humansJournal of Medical Genetics, 2003
- Immunophenotyping of blood lymphocytes in childhoodReference values for lymphocyte subpopulationsThe Journal of Pediatrics, 1997
- Hepatic Dysfunction as a Complication of Adenosine Deaminase DeficiencyNew England Journal of Medicine, 1996